Atreca Further Strengthens Management Team with Appointment of Lisa Decker as Chief Business Officer and Courtney Phillips as...
July 11 2019 - 8:00AM
Atreca, Inc. (NASDAQ: BCEL), a biotechnology company focused on
developing novel therapeutics based on a deep understanding of the
human immune response, today announced the appointment of Lisa L.
Decker, Ph.D., as Chief Business Officer and Courtney J. Phillips
as General Counsel.
“I am incredibly excited to have both Lisa and Courtney joining
Atreca at this pivotal time as we work to broaden our research and
development pipeline and prepare to move ATRC-101 into the clinic
in early 2020,” said John Orwin, Chief Executive Officer.
“Our ability to build out our leadership team with individuals of
this caliber is not only critical to achieving our strategic
objectives but is a testament to the ground-breaking research being
done and the platform that we’ve built here at Atreca.”
Chief Business OfficerAs Chief Business
Officer, Dr. Decker will lead Atreca’s corporate development
function, including its strategic partnering initiatives and
alliance management. As a senior executive with experience in
negotiating and executing strategic partnerships in all areas and
stages of biopharmaceutical development, Dr. Decker is ideally
suited for this role. Prior to joining Atreca, she served as the
Vice President of Business Development at Nektar Therapeutics. In
that role, she was responsible for all partnering activities,
including most recently leading negotiations for their broad-based
clinical collaborations with Bristol Meyers Squibb on
NKTR-214. Dr. Decker also executed multiple additional
research collaborations over more than ten years at Nektar with
partners such as Pfizer, Eli Lilly, Takeda, and Gilead. Prior to
joining Nektar, Dr. Decker was the Associate Director of Technology
Licensing at the University of Massachusetts Medical School where
she led the partnering and intellectual property strategy efforts
for a diverse array of early stage technologies, including the
University's Nobel Prize winning RNAi portfolio. Dr. Decker
holds a Ph.D. in Immunology from Tufts University School of
Medicine and conducted her postdoctoral training at Harvard Medical
School.
General CounselAs General Counsel, Ms. Phillips
will lead Atreca’s legal, compliance and intellectual property
functions. She is a seasoned attorney with deep experience leading
corporate and transactional matters at public biopharmaceutical
companies, including corporate governance, compliance, contracting,
securities law matters and SEC reporting, financings, and
employment law matters. Prior to joining Atreca, Ms. Phillips was
the Vice President of Corporate Law at Global Blood Therapeutics,
where she led a broad range of legal activities. Prior to
joining Global Blood Therapeutics, she was Senior Counsel and then
Vice President and Associate General Counsel at Relypsa where she
led a wide variety of legal matters as the company transitioned
from IPO through commercialization of its first product and
acquisition by Galenica. Prior to joining Relypsa, she was
Corporate Counsel at Affymax. Earlier in her career, Ms. Phillips
was a corporate attorney at the law firms of Morrison Foerster LLP
and Reed Smith LLP, where she represented public and private life
science and technology companies in mergers and acquisitions,
securities law matters and equity financings. Ms. Phillips holds a
J.D. from Georgetown University Law Center and a B.A. from the
University of California, Berkeley.
About Atreca, Inc. Atreca is a
biopharmaceutical company utilizing its differentiated platform to
discover and develop novel antibody-based immunotherapeutics to
treat a range of solid tumor types. Atreca’s discovery
platform relies on the human immune system to discover unique
antibody-target pairs from patients experiencing an active immune
response against their tumors. These unique antibody-target pairs
represent a potentially novel and previously unexplored landscape
of immuno-oncology targets and provide the basis for novel clinical
therapeutic candidates such as ATRC-101, the company’s lead
clinical candidate. The company expects to file an
Investigational New Drug application for ATRC-101 by the end of
2019 and to commence a Phase 1b study in multiple solid tumor types
in early 2020. For more information on Atreca, please visit
www.atreca.com.
Forward-Looking Statements This release
contains forward-looking statements regarding our strategy and
future plans, including statements regarding the development of
ATRC-101 and our clinical and regulatory plans. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as “may,” “will”, “should,” “on
track,” “could,” “expect,” “plan,” “anticipate,” “believe,”
“estimate,” “predict,” “potential,” “continue” and similar words,
although some forward-looking statements are expressed differently.
Our actual results may differ materially from those indicated in
these forward-looking statements due to risks and uncertainties
related to the initiation, timing, progress and results of our
research and development programs, preclinical studies, any
clinical trials and Investigational New Drug application and other
regulatory submissions, and other matters that are described in our
prospectus, dated June 19, 2019, as filed with the Securities and
Exchange Commission (SEC) pursuant to Rule 424(b) under the
Securities Act of 1933, as amended, which is available on the SEC’s
website at www.sec.gov, including the risk factors set forth
therein. Investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
of this release, and we undertake no obligation to update any
forward-looking statement in this press release, except as required
by law.
ContactsAtreca, Inc. Herb Cross Chief Financial
Officer info@atreca.com or Media: Nancie Steinberg, 212-213-0006,
ext. 318nsteinberg@burnsmc.com or Investors: Alex Gray,
650-779-9251, ext. 251 agray@atreca.com
Source: Atreca, Inc.
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024